Bli medlem
Bli medlem

Du är här


Medivir: Redeye: Medivir - Pipeline progress

The Medivir case has been moving in a positive direction since our
initiation of coverage in May, and especially the MIV-818 program,
which has shown encouraging first-in-human results. We have also seen
the restructuring savings having an impact on the cash burn, somewhat
faster than we expected, why we believe the cash balance of SEK 192m
at the end of Q2 finances operations into late-2020 (prev. mid-2020).

Read more and download the research update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.